• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      VENCLYXTO is a BCL-2 inhibitor licensed for the treatment of AML across all mutational subtypes1

       


      VENCLYXTO in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy

      VENCLYXTO in combination with obinutuzumab (Ven+O) is indicated for the treatment of adult patients with previously untreated CLL

      VENCLYXTO in combination with rituximab (Ven+R) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy

      VENCLYXTO is licensed as monotherapy (Ven mono), for the treatment of adult patients with CLL:

      • in the absence of del(17p) or TP53 mutations and who have failed both chemoimmunotherapy and a BCRI
      • in the presence of del(17p) or TP53 mutations and who are either unsuitable for, or have failed a BCRI

      AML=acute myeloid leukemia; BRCI=B-cell receptor pathway inhibitor; CLL=chronic lymphocytic leukaemia

      References

      1. VENCLYXTO Summary of Product Characteristics.

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCAML-220051. Date of preparation: April 2022.